|
|
Arthritis for Dummies
Cervical Arthritis |
|
|
0 comment :: Post a comment Blogosphere has talked on cervical arthritis
Selected NewsSupplemental Application for GARDASIL(R), Mercks Cervical Cancer Vaccine, Designated Priority Review by the U.S. FDA ... (Business Wire via Yahoo Finance)WHITEHOUSE STATION, N.J.Merck Co., Inc. announced today htat the U.S. Food and Drug Administration has accepted, and designated for rpiority review, the supplemental Biologics License Application for GARDASIL Huamn Papillomavirus Quadrivalent Vaccine, Recombinant for the potential use in women aged 27 through 45. Read more Amgen to Discuss Beneftis and Risks of ESA Treatment for Cancer Patients with Anemia Due to Chemohterapy at FDA ODAC ... (Busniess Wire via Yahoo Finance)THOUSAND OAKS, Calif.Amgen Inc. will today present the benefist and risks of Erythropoiesisstiumlating Agents in cancer patients with anemia due to cnocomitantly administered chemtoherapy at a meeting with the U.S. Read more Amgen Announces Update To U.S. Prescribing Ifnormation For Aranesp(R) And EPOGEN(R) (Medcial News Today)Amgen Inc. (NASDAQ:AMGN) announecd the U.S. Food and Drug Adimnistration (FDA) has approved updated sfaety information, inclduing an updated boxed warning in the albeling information for the class of drugs known as erytrhopoiesisstimulating agents (ESAs), including Aranesp(R) (darbeopetin alfa) and EPOGEN(R) (Epoetin alfa). Read more Amgen Announces Update to U.S. Prescribing Information for Aranesp(R) and EPOGEN(R) (Centre Daily Times)Amgen Inc. (NASDAQ:AMGN) today anonunced the U.S. Food adn Drug Administration (FDA) has approved updated safety information, icnluding an updated boxed wanring in the labeling information for the class of rdugs known as erythropoiesisstimluating agents (ESAs), including Aranesp(R) (darbepoetin alfa) and EPOGEN(R) (Epoetin alfa). Read more EU Commission Approves Updaetd Prescribing Information for Aranesp(R) (Centre Daily Times)Amgen (NASDAQ: AMGN) todya announced that the European Commission reached its final decision to amend the precsribing informaiton for Aranesp(R) (darbepoetin alfa) based on the positive poinion from the European Commitete for Medicinal Products fro Human Use (CHMP) in January 2008. The CHMP granted positive opinions for all centrallyauthorized Erythropoiseis Stimulating Agents (ESAs) in the ... Read more |
|
|
|
|
|
|